Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection

Nathalie Adda; Doug J. Bartels; Linda Gritz; Tara L. Kieffer; Frank Tomaka; Leif Bengtsson; Don Luo; Ira M. Jacobson; Robert S. Kauffman; Gaston Picchio

doi:10.1016/j.cgh.2012.10.045

Back

Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection

Journal article

Open access

Peer reviewed

Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection

Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L. Kieffer, Frank Tomaka, Leif Bengtsson, Don Luo, Ira M. Jacobson, Robert S. Kauffman and Gaston Picchio

Clinical gastroenterology and hepatology, Vol.11(2), pp.193-195

02/2013

DOI: 10.1016/j.cgh.2012.10.045

PMID: 23159528

Files and links (1)

url

https://doi.org/10.1016/j.cgh.2012.10.045View

Published (Version of record) Open Access

Abstract

For patients treated with telaprevir, peginterferon, and ribavirin, futility rules have been developed to prevent needless drug exposure and minimize development of drug-resistant variants for patients who have little or no chance of achieving a sustained virologic response. We performed retrospective analyses of data from phase 3 trials and validated the current futility rule. All therapy should be stopped for treatment-naive and treatment-experienced patients if hepatitis C virus RNA levels are greater than 1000 IU/mL at weeks 4 or 12, or if hepatitis C virus RNA is detectable at week 24.

Chronic Hepatitis

Protease Inhibitor

SVR

Details

Title: Subtitle: Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection
Creators: Nathalie Adda - Vertex Pharmaceuticals (United States)
Doug J. Bartels - Vertex Pharmaceuticals (United States)
Linda Gritz - Vertex Pharmaceuticals (United States)
Tara L. Kieffer - Vertex Pharmaceuticals (United States)
Frank Tomaka - Janssen (United States)
Leif Bengtsson - Vertex Pharmaceuticals (United States)
Don Luo - Janssen (United States)
Ira M. Jacobson - Cornell University
Robert S. Kauffman - Vertex Pharmaceuticals (United States)
Gaston Picchio - Janssen (United States)
Resource Type: Journal article
Publication Details: Clinical gastroenterology and hepatology, Vol.11(2), pp.193-195
DOI: 10.1016/j.cgh.2012.10.045
PMID: 23159528
NLM abbreviation: Clin Gastroenterol Hepatol
ISSN: 1542-3565
eISSN: 1542-7714
Publisher: Elsevier Inc
Grant note: Human Genome Sciences GlobeImmune Bristol-Myers Squibb Gilead Sciences Pharmasset Novartis Schering-Plough/Merck Anadys Pharmaceuticals Tibotec/Janssen Roche/Genentech Abbott Vertex Pharmaceuticals Incorporated Boehringer Ingelheim Achillion
Language: English
Date published: 02/2013
Academic Unit: Anatomy and Cell Biology
Record Identifier: 9984284329702771

Metrics

9 Record Views

7 Times Cited - Web of Science